A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in combination with Durvalumab, Carboplatin and Etoposide versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312)

2008). Around 70% of patients are diagnosed with ES-SCLC, 2015), 2016). It displays a distinct natural history characterized by a high growth fraction, accounting for 10% to 15% of lung cancer (Rudin et al, Extensive stage small cell lung cancer (ES-SCLC). Small-cell lung cancer, is an aggressive lung cancer subtype with neuroendocrine differentiation and strongly associated with smoking (Koinis et al, presenting with distant metastasis or tumor or nodal volume that is too large to be encompassed in a tolerable radiation plan., rapid doubling time and early establishment of widespread metastatic lesions (Gustafsson et al

OS

PFS, OR, DC, DOR, PFS rate at 6 months, 1 year, and 2 years from randomization OS rate at 6 months, 1 year, 2 years, and 3 years from randomization TTP, Incidence of treatment-emergent adverse events, Serum concentrations of tarlatamab., Incidence of anti-tarlatamab antibody formation.

No related papers found yet.

Austria, Belgium, Denmark, France, Germany, Greece, Hungary, Italy, Netherlands, Poland, Portugal, Romania, Spain